Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients with activating EGFR Mutations

Trial Identifier: D5161R00017
Sponsor: AstraZeneca
Start Date: May 2021
Primary Completion Date: January 2026
Study Completion Date: January 2026
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
France ABBEVILLE CEDEX, France
France AIX EN PROVENCE CEDEX 1, France
France ANGERS CEDEX 01, France
France ANTIBES CEDEX, France
France AVIGNON CEDEX 9, France
France BASTIA CEDEX, France
France BAYONNE, France
France BORDEAUX CEDEX, France
France BOURG EN BRESSE, France
France BREST, France
France CANNES CEDEX, France
France CHAMBERY CEDEX, France
France CHAUNY CEDEX, France
France CHOLET, France
France CLERMONT-FERRAND, France
France COLMAR CEDEX, France
France CONTAMINE-SUR-ARVE, France
France CRETEIL, France
France ELBEUF CEDEX, France
France EPAGNY METZ TESSY, France
France EVREUX, France
France LA ROCHE SUR YON, France
France LIBOURNE, France
France LIMOGES CEDEX, France
France LYON, France
France MARSEILLE, France
France MARSEILLE CEDEX 08, France
France MEAUX CEDEX, France
France MULHOUSE, France
France ORLEANS, France
France PARIS, France
France POITIERS CEDEX, France
France QUIMPER, France
France REIMS CEDEX, France
France ROUEN CEDEX, France
France SAINT DENIS, France
France SAINT PIERRE, France
France SAINT-GREGOIRE, France
France SAINT-QUENTIN CEDEX, France
France TOULON CEDEX 9, France
France TOULOUSE CEDEX 9, France
France VALENCIENNES, France
France VANNES, France
France VILLEFRANCHE-SUR-SAONE, France
France VILLENAVE-DORNON, France
France VILLEURBANNE, France